Company Overview
Alzamend Neuro, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the development of various products designed for the treatment of neurodegenerative and psychiatric disorders. The firm specifically focuses its research pipeline on AL001, a therapeutic combination of lithium, proline, and salicylate intended for the treatment of Alzheimer's disease. This entity functions within the healthcare sector, specifically the biotechnology industry, a domain characterized by high capital expenditure, long development cycles, and significant regulatory hurdles before products reach commercialization. The company's current scale is defined by a market capitalization of $3.99 million, an annual revenue of N/A, and an employee count of 4. These valuation and operational metrics indicate that Alzamend Neuro is a micro-cap entity with a very small operational footprint, suggesting that the company is in a pre-revenue or early-stage development phase where value is derived primarily from intellectual property potential rather than current cash flows or established market share.
Financial Health
The company reports a Net Income of $-7,544,730 and an EBITDA of $-6,939,160 over the trailing twelve months, while Revenue remains N/A. The substantial gap between the reported net income and EBITDA figures reveals that the company's cost structure is heavily influenced by non-operating expenses, likely related to interest, taxes, or significant one-time costs not captured in the EBITDA calculation, given that EBITDA is less negative than the net income loss. Free Cash Flow stands at $-3,615,899, which indicates that the company is consuming cash to fund its operations and research activities rather than generating liquidity from current business activities. All three margins—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that suggests the company has not yet generated sufficient revenue to cover its cost of goods sold or operating expenses to create a positive profit environment. Total cash on hand amounts to $2.71 million, while total debt is N/A, and the debt-to-equity ratio is also N/A. In the absence of recorded debt, the balance sheet relies entirely on its cash reserves to support ongoing operations, presenting a conservative capital structure typical of early-stage biotech firms that have not yet accumulated leverage. The Current Ratio is 1.99, indicating that the company holds nearly twice the amount of current assets relative to its current liabilities, which suggests a strong position regarding short-term liquidity and the ability to meet obligations as they come due. Return on Equity is -250.0% and Return on Assets is -107.0%, metrics that reveal that management is currently utilizing shareholder and asset bases to generate significant losses rather than positive returns, reflecting the high-risk nature of clinical-stage development.
Valuation Assessment
The trailing P/E Ratio is N/A due to the lack of positive earnings, while the Forward P/E is -0.40, a metric that implies the market is pricing the stock based on future expectations despite current losses. The Price to Book ratio is 1.83, indicating that the market values the company at 1.83 times its book value, which suggests a premium over the net asset value often seen in biotechnology companies with valuable intellectual property pipelines. The Price to Sales ratio is N/A because revenue data is unavailable, and the EV/EBITDA stands at -0.18, providing an alternative valuation perspective that remains negative due to the company's current lack of earnings before interest, taxes, depreciation, and amortization. The stock's 52-week high is $10.17 and the 52-week low is $1.01, establishing a trading range where the current price position relative to this range fluctuates based on daily market movements and investor sentiment regarding the clinical progress of its pipeline. The Beta value is -0.24, a highly unusual negative figure that implies the stock's price volatility moves inversely to the broader market or that the calculation methodology for this specific low-cap stock results in a negative correlation coefficient.
Growth & Income
Revenue Growth is N/A and Earnings Growth is N/A as the company has not yet established a consistent track record of commercial sales to calculate year-over-year percentage changes. The absence of positive revenue growth data implies that the company is not yet in a commercial scaling phase where earnings could theoretically grow faster or slower than revenue, as the primary focus remains on product development. As a non-dividend payer, the company does not distribute a Dividend Yield or a Payout Ratio, meaning the firm reinvests all available resources and any generated cash flow directly back into research and development rather than paying shareholders. The overall growth and income profile is characterized by a reliance on future clinical trial successes and regulatory approvals to transition from a cash-burning clinical-stage entity into a revenue-generating commercial business.